Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in Lymphomas

“Some work that needs to be done would be development of products which have lower manufacturing time, another would be a more rapid process for financial clearance for commercial parties. We need to understand that the disease is aggressive in many cases, and we just can't wait 4 weeks to get clearance. Another thing would be building relationships with physicians and educating them about indications for CAR T.”

The last few years have seen chimeric antigen receptor (CAR) T-cell therapy approvals in hematologic malignancies including lisocabtagenemaraleucel (Breyanzi), axicabtagenecliolecleucel (Yescarta), brexucabtageneautoleucel (Tecartus) and ciltacabtageneautoleucel (Carvykti). With these approvals, clinicians are beginning to see the long-term impact of these treatments in the clinic

Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is one such clinician with first-hand experience with cell therapies in lymphoma. CGTLive spoke to Ghosh to learn more about work that needs to be done to support the growing prominence of CAR T-cell therapies in cancer treatment and future therapies to come to market. He also noted some questions that remain to be researched with these cell therapies.